Wall Street analysts expect that Editas Medicine Inc (NASDAQ:EDIT) will post earnings per share of ($0.59) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Editas Medicine’s earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.80). Editas Medicine posted earnings per share of ($0.82) in the same quarter last year, which indicates a positive year over year growth rate of 28%. The company is scheduled to report its next quarterly earnings report on Monday, August 5th.
On average, analysts expect that Editas Medicine will report full-year earnings of ($2.52) per share for the current fiscal year, with EPS estimates ranging from ($3.13) to ($1.88). For the next financial year, analysts expect that the firm will report earnings of ($2.87) per share, with EPS estimates ranging from ($3.15) to ($2.68). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Editas Medicine.
Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, May 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.03). Editas Medicine had a negative net margin of 359.93% and a negative return on equity of 47.64%. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $7.62 million. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. The company’s revenue for the quarter was down 47.3% compared to the same quarter last year.
Large investors have recently bought and sold shares of the stock. Creative Planning raised its holdings in Editas Medicine by 7.6% during the 1st quarter. Creative Planning now owns 26,504 shares of the company’s stock valued at $648,000 after buying an additional 1,879 shares during the last quarter. Capital Impact Advisors LLC raised its holdings in Editas Medicine by 10.9% during the 4th quarter. Capital Impact Advisors LLC now owns 63,637 shares of the company’s stock valued at $1,319,000 after buying an additional 6,231 shares during the last quarter. 361 Capital LLC bought a new stake in Editas Medicine during the 4th quarter valued at $2,097,000. Squarepoint Ops LLC raised its holdings in Editas Medicine by 49.8% during the 4th quarter. Squarepoint Ops LLC now owns 84,319 shares of the company’s stock valued at $1,918,000 after buying an additional 28,019 shares during the last quarter. Finally, FDx Advisors Inc. bought a new stake in Editas Medicine during the 4th quarter valued at $241,000. Institutional investors own 75.43% of the company’s stock.
Editas Medicine stock traded down $0.53 during mid-day trading on Friday, hitting $21.88. 857 shares of the company traded hands, compared to its average volume of 640,369. Editas Medicine has a one year low of $17.80 and a one year high of $41.43. The firm has a market cap of $1.10 billion, a PE ratio of -9.44 and a beta of 2.47. The company has a debt-to-equity ratio of 0.07, a current ratio of 8.46 and a quick ratio of 8.46.
Editas Medicine Company Profile
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.
See Also: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.